Geron, is leaving the stem cell research for spinal cord regeneration behind and moving on to cancer drugs. They cite financial reasons. It's simply too expensive to continue.
http://blogs.discovermagazine.com/80...-the-business/
http://blogs.discovermagazine.com/80...-the-business/
Comment